Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptal653adk

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

```
 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2          "Ask CAS" for self-help around the clock
 NEWS  3  FEB 28  PATDPAFULL - New display fields provide for legal status
                  data from INPADOC
 NEWS  4  FEB 28  BABS - Current-awareness alerts (SDIs) available
 NEWS  5  MAR 02  GBFULL: New full-text patent database on STN
 NEWS  6  MAR 03  REGISTRY/ZREGISTRY - Sequence annotations enhanced
 NEWS  7  MAR 03  MEDLINE file segment of TOXCENTER reloaded
 NEWS  8  MAR 22  KOREAPAT now updated monthly; patent information enhanced
 NEWS  9  MAR 22  Original IDE display format returns to REGISTRY/ZREGISTRY
 NEWS  10 MAR 22  PATDPASPC - New patent database available
 NEWS  11 MAR 22  REGISTRY/ZREGISTRY enhanced with experimental property tags
 NEWS  12 APR 04  EPFULL enhanced with additional patent information and new
                  fields
 NEWS  13 APR 04  EMBASE - Database reloaded and enhanced
 NEWS  14 APR 18  New CAS Information Use Policies available online
 NEWS  15 APR 25  Patent searching, including current-awareness alerts (SDIs),
                  based on application date in CA/CAplus and USPATFULL/USPAT2
                  may be affected by a change in filing date for U.S.
                  applications.
 NEWS  16 APR 28  Improved searching of U.S. Patent Classifications for
                  U.S. patent records in CA/CAplus
 NEWS  17 MAY 23  GBFULL enhanced with patent drawing images
 NEWS  18 MAY 23  REGISTRY has been enhanced with source information from
                  CHEMCATS
 NEWS  19 JUN 06  STN Patent Forums to be held in June 2005
 NEWS  20 JUN 06  The Analysis Edition of STN Express with Discover!
                  (Version 8.0 for Windows) now available
 NEWS  21 JUN 13  RUSSIAPAT: New full-text patent database on STN
 NEWS  22 JUN 13  FRFULL enhanced with patent drawing images
 NEWS  23 JUN 20  MEDICONF to be removed from STN

 NEWS EXPRESS  JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 07:28:10 ON 24 JUN 2005

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 07:28:19 ON 24 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 JUN 2005 HIGHEST RN 852898-09-0
DICTIONARY FILE UPDATES: 23 JUN 2005 HIGHEST RN 852898-09-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****

* *

* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *

* *

****

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading H:\STN queries\09879442i.str



chain nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32
chain bonds :
1-3 1-2 3-4 3-29 4-5 5-6 5-7 6-8 6-17 9-14 9-10 9-18 10-11 11-12 11-13 14-15 15-16 15-20 17-18 18-19 20-21 21-22 22-23 23-24 23-25 25-26 26-28 26-27 29-30 30-31 30-32
exact/norm bonds :
1-2 3-4 4-5 5-7 6-17 9-14 14-15 15-16 17-18 18-19 21-22 22-23 23-24 23-25 25-26 26-28 26-27
exact bonds :
1-3 3-29 5-6 6-8 9-10 9-18 10-11 11-12 11-13 15-20 20-21 29-30 30-31 30-32

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS

L1 STRUCTURE UPLOADED

=> dis l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful
FULL SEARCH INITIATED 07:28:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 168398 TO ITERATE

100.0% PROCESSED 168398 ITERATIONS 21 ANSWERS
SEARCH TIME: 00.00.14

L2 21 SEA SSS FUL L1

=> e doxorubicin

E1	109	DOXORUBI/BI
E2	2	DOXORUBICI/BI
E3	109 -->	DOXORUBICIN/BI
E4	6	DOXORUBICINOL/BI
E5	2	DOXORUBICINOLONE/BI
E6	2	DOXORUBICINON/BI
E7	2	DOXORUBICINONE/BI
E8	2	DOXPICO/BI
E9	2	DOXPICODI/BI
E10	2	DOXPICODIN/BI
E11	2	DOXPICOMINE/BI
E12	1	DOXS/BI

=> s e3
L3 109 DOXORUBICIN/BI

=> l3 and l2
L4 0 L3 AND L2

=> fil hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	166.36	166.57

FILE 'HCAPLUS' ENTERED AT 07:29:39 ON 24 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 24 Jun 2005 VOL 143 ISS 1
FILE LAST UPDATED: 23 Jun 2005 (20050623/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L5 13 L2

=> d l5 1-13 ed

L5 ANSWER 1 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 25 Feb 2005

L5 ANSWER 2 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 18 Oct 2004

L5 ANSWER 3 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 24 Sep 2004

L5 ANSWER 4 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 20 Sep 2004

L5 ANSWER 5 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 19 Sep 2003

L5 ANSWER 6 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 20 Dec 2002

L5 ANSWER 7 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 06 Dec 2002

L5 ANSWER 8 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 04 Oct 2002

L5 ANSWER 9 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 01 May 2002

L5 ANSWER 10 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 04 Jan 2002

L5 ANSWER 11 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 21 Dec 2001

L5 ANSWER 12 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 07 Sep 2001

L5 ANSWER 13 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 16 Jun 2000

=> d l2 1-13 ibib hitstr
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:y

'IBIB' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'
'HITSTR' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

REG - RN
SAM - Index Name, MF, and structure - no RN
FIDE - All substance data, except sequence data
IDE - FIDE, but only 50 names
SQIDE - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD - Protein sequence data, includes RN
SQD3 - Same as SQD, but 3-letter amino acid codes are used
SQN - Protein sequence name information, includes RN

CALC - Table of calculated properties
EPROP - Table of experimental properties
PROP - EPROP and CALC

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract
APPS -- Application and Priority Information
BIB -- CA Accession Number, plus Bibliographic Data
CAN -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND -- Index Data
IPC -- International Patent Classification
PATS -- PI, SO
STD -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.
The MAX format is the same as ALL.
The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
ENTER DISPLAY FORMAT (IDE):end

=> d l5 1-13 ibib hitstr

L5 ANSWER 1 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:159927 HCAPLUS Full-text
DOCUMENT NUMBER: 142:254652
TITLE: Potentiation of the activation of high-molecular-weight prodrugs for therapeutic or diagnostic use
INVENTOR(S): Trouet, Andre; Dubois, Vincent
PATENT ASSIGNEE(S): Diatos, Fr.
SOURCE: Fr. Demande, 64 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2858936	A1	20050225	FR 2003-10114	20030822
WO 2005021043	A2	20050310	WO 2004-FR2162	20040819

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: FR 2003-10114 A 20030822
IT 274912-87-7
RL: PAC (Pharmacological activity); BIOL (Biological study) (potentiation of activation of high-mol.-weight prodrugs for therapeutic or diagnostic use)
RN 274912-87-7 HCAPLUS
CN 5,12-Naphthacenedione, 10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:857758 HCAPLUS Full-text
DOCUMENT NUMBER: 141:325667
TITLE: Allosteric nucleic acid probes and their use in disease diagnosis and treatment
INVENTOR(S): Nilsen-Hamilton, Marit
PATENT ASSIGNEE(S): Iowa State University Research Foundation, Inc., USA
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004088279	A2	20041014	WO 2004-US9381	20040326

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,

BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005026178 A1 20050203 US 2004-809886 20040326
PRIORITY APPLN. INFO.: US 2003-457936P P 20030328

IT 274912-87-7, CPI-0004Na
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(allosteric regulator or target; allosteric nucleic acid probes and their use in diseases diagnosis and treatment)

RN 274912-87-7 HCAPLUS

CN 5,12-Naphthacenedione, 10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B



L5 ANSWER 3 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:780503 HCAPLUS Full-text
DOCUMENT NUMBER: 141:289012
TITLE: Paclitaxel hybrid derivatives with improved properties for the treatment of cancer
INVENTOR(S): Erhardt, Paul W.; Klis, Weislaw A.; Sarver, Jeffrey G.
PATENT ASSIGNEE(S): The University of Toledo, USA
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004080412	A2	20040923	WO 2004-US7269	20040305
WO 2004080412	A3	20050526		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-452649P P 20030307
OTHER SOURCE(S): MARPAT 141:289012

IT 274913-04-1D, conjugates with paclitaxel
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(paclitaxel derivs. with improved properties for treatment of cancer)

RN 274913-04-1 HCAPLUS

CN L-Leucine, N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 4 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:765541 HCAPLUS Full-text
DOCUMENT NUMBER: 142:106748
TITLE: CPI-0004Na, a new doxorubicin prodrug, reduces growth of 3LL-H61 carcinoma lung metastases in C57B1/6 mice
AUTHOR(S): Dasnois, Luc; Lebtahi, Karim; Abarca-Quinones, Jorge; Havaux, Nathalie; Dupont, Samuel; Dubois, Vincent; Trouet, Andre
CORPORATE SOURCE: Laboratory of Cell Biology & Institut des Sciences de la Vie, Universite catholique de Louvain, Louvain-La-Neuve, B-1348, Belg.
SOURCE: Journal of Experimental Therapeutics and Oncology (2004), 4(2), 167-169
CODEN: JETOFX; ISSN: 1359-4117
PUBLISHER: Old City Publishing
DOCUMENT TYPE: Journal
LANGUAGE: English

IT 274912-87-7, CPI 0004Na
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(doxorubicin prodrug CPI-0004Na significantly reduced 3LL-H61 carcinoma cell lung metastases in mouse than doxorubicin suggesting its potent anti-tumor activity)

RN 274912-87-7 HCAPLUS

CN 5,12-Naphthacenedione, 10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:733803 HCAPLUS Full-text
DOCUMENT NUMBER: 140:156884
TITLE: CD10 Is a Key Enzyme Involved in the Activation of Tumor-activated Peptide Prodrug CPI-0004Na and Novel Analogues: Implications for the Design of Novel Peptide Prodrugs for the Therapy of CD10+ Tumors
AUTHOR(S): Pan, Chin; Cardarelli, Pina M.; Nieder, Matthew H.; Pickford, Lesley B.; Gangwar, Sanjeev; King, David J.; Yarranton, Geoffrey T.; Buckman, Dana; Roscoe, William; Zhou, Fengmin; Salles, Adam; Chen, Tseng-Hui; Horgan, Killian; Wang, Yi-Hong; Nguyen, Thi; Bebbington, Christopher R.
CORPORATE SOURCE: Corixa Corp., South San Francisco, CA, 94080, USA
SOURCE: Cancer Research (2003), 63(17), 5526-5531
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

IT 274912-87-7, CPI 0004Na
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(metalloprotease CD10 role in activation of tumor-activated peptide prodrug CPI-0004Na and novel analogs)

RN 274912-87-7 HCAPLUS

CN 5,12-Naphthacenedione, 10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:964147 HCAPLUS Full-text
DOCUMENT NUMBER: 138:29142
TITLE: CD10-activated prodrug compounds
INVENTOR(S): Bebbington, Christopher R.; Nieder, Matthew H.; Cardarelli, Pina M.; Gangwar, Sanjeev; Pickford, Lesley B.; Pan, Chin
PATENT ASSIGNEE(S): Medarex, Inc., USA
SOURCE: PCT Int. Appl., 167 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100353	A2	20021219	WO 2002-US21135	20020610
WO 2002100353	A3	20030522		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2450316	AA	20021219	CA 2002-2450316	20020611
EP 1404356	A2	20040407	EP 2002-746852	20020611
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004087497	A1	20040506	US 2002-167627	20020611
US 6897034	B2	20050524		
JP 2004537527	T2	20041216	JP 2003-503179	20020611
PRIORITY APPLN. INFO.:			US 2001-297596P P	20010611
			WO 2002-US21135 W	20020611

OTHER SOURCE(S): MARPAT 138:29142
IT 274912-87-7P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(oligopeptide-containing prodrugs activated by CD10 antigen)
RN 274912-87-7 HCAPLUS
CN 5,12-Naphthacenedione, 10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B



IT 274912-96-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(oligopeptide-containing prodrugs activated by CD10 antigen)
RN 274912-96-8 HCAPLUS
CN L-Leucine, N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 274913-07-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(oligopeptide-containing prodrugs activated by CD10 antigen)
RN 274913-07-4 HCAPLUS
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B



L5 ANSWER 7 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:927432 HCAPLUS Full-text
DOCUMENT NUMBER: 138:4470
TITLE: Preparation of duocarmycin analogs as potent cytotoxins
INVENTOR(S): Ng, Howard P.; McGee, Danny P. C.; Wu, Guoxian; Li, Zhihong; Gangwar, Sanjeev; Saunders, Oliver L.; Martichonok, Valeri; Astafieva, Irina; Moore, Jimmie; Yarranton, Geoffrey Thomas; King, David J.; Boyd, Sharon; Lobl, Thomas J.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096910	A1	20021205	WO 2002-US17210	20020531
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2448319	AA	20021205	CA 2002-2448319	20020531
US 2003050331	A1	20030313	US 2002-160972	20020531
US 2003064984	A1	20030403	US 2002-161234	20020531
US 2003073852	A1	20030417	US 2002-161233	20020531
NZ 529788	A	20031219	NZ 2002-529788	20020531
EP 1434778	A1	20040707	EP 2002-731994	20020531
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005500273	T2	20050106	JP 2003-500089	20020531
ZA 2003000735	A	20040623	ZA 2003-735	20030128
PRIORITY APPLN. INFO.:			US 2001-295196P P	20010531
			US 2001-295259P P	20010531
			US 2001-295342P P	20010531
			US 2001-304908P P	20010711
			WO 2002-US17210 W	20020531

OTHER SOURCE(S): MARPAT 138:4470
IT 477209-22-6P 477209-52-2P 477209-54-4P
477209-56-6P 477209-59-9P 477209-60-2P
477209-62-4P 477209-63-5P 477209-64-6P
477209-66-8P 477328-64-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of duocarmycin analogs as potent cytotoxins)
RN 477209-22-6 HCAPLUS
CN L-Leucinamide, N-[1,4-dioxo-4-(phenylmethoxy)butyl]-β-alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[(1S)-1-(chloromethyl)-8-cyano-1,2-dihydro-5-hydroxy-3H-benz[e]indol-3-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-5-benzofuranyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B



RN 477209-52-2 HCAPLUS

CN L-Leucinamide, N-[1,4-dioxo-4-(phenylmethoxy)butyl]-β-alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[(1S)-1-(chloromethyl)-5-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1,6-dihydro-8-(methoxycarbonyl)-7-methylbenzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-5-benzofuranyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 477209-54-4 HCAPLUS

CN L-Leucinamide, N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[(1S)-1-(chloromethyl)-5-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1,6-dihydro-8-(methoxycarbonyl)-7-methylbenzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-5-benzofuranyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 477209-59-9 HCAPLUS

CN L-Leucinamide, N-(5-carboxy-1-oxopentyl)-β-alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[(1S)-1-(chloromethyl)-1,6-dihydro-8-(methoxycarbonyl)-7-methyl-5-[[(4-methyl-1-piperazinyl)carbonyl]oxy]benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



1,6-dihydro-8-(methoxycarbonyl)-7-methylbenzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-5-benzofuranyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 477209-56-6 HCAPLUS

CN L-Leucinamide, N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[(1S)-1-(chloromethyl)-1,6-dihydro-5-hydroxy-8-(methoxycarbonyl)-7-methylbenzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-5-benzofuranyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B



PAGE 2-A

RN 477209-60-2 HCAPLUS

CN L-Leucinamide, N-(6-methoxy-1,6-dioxohexyl)-β-alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[(1S)-1-(chloromethyl)-1,6-dihydro-8-(methoxycarbonyl)-7-methyl-5-[[(4-methyl-1-piperazinyl)carbonyl]oxy]benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A

RN 477209-62-4 HCAPLUS

CN L-Leucinamide, N-(1,6-dioxo-6-(phenylmethoxy)hexyl)-β-alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[(1S)-1-(chloromethyl)-1,6-dihydro-8-(methoxycarbonyl)-7-methyl-5-[[(4-methyl-1-piperazinyl)carbonyl]oxy]benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A

RN 477209-64-6 HCAPLUS

CN L-Leucinamide, N-(5-carboxy-1-oxopentyl)-β-alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[(1S)-1-(chloromethyl)-1,6-dihydro-5-hydroxy-8-(methoxycarbonyl)-7-methylbenzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-B



PAGE 2-A

RN 477209-63-5 HCAPLUS

CN L-Leucinamide, N-[1,4-dioxo-4-(phenylmethoxy)butyl]-β-alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[(1S)-1-(chloromethyl)-1,6-dihydro-8-(methoxycarbonyl)-7-methyl-5-[[(4-methyl-1-piperazinyl)carbonyl]oxy]benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



RN 477209-66-8 HCAPLUS

CN L-Leucinamide, N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[(1S)-1-(chloromethyl)-1,6-dihydro-8-(methoxycarbonyl)-7-methyl-5-[[(4-methyl-1-piperazinyl)carbonyl]oxy]benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A

RN 477328-64-6 HCAPLUS

CN Leucinamide, N-(3-carboxy-1-oxopropyl)-β-alanylleucylalanyl-N-[6-[[2-[[[2-[[(1S)-1-(chloromethyl)-1,6-dihydro-5-hydroxy-8-(methoxycarbonyl)-7-methylbenzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-5-benzofuranyl]amino]-6-oxohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:755199 HCAPLUS Full-text
DOCUMENT NUMBER: 137:284323
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Dubois, Vincent; Fernandez, Anne Marie; Gangwar, Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Belg.
SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl. No. PCT/US99/30393.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002142955	A1	20021003	US 2001-879442	20010611
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 1998-111793P	P	19981211
US 1999-119312P	P	19990208
WO 1999-US30393	A2	19991210
US 2000-211887P	P	20000614
US 2001-290448P	P	20010511

OTHER SOURCE(S): MARPAT 137:284323

IT 274912-87-7P 274912-88-8P 274912-89-9P
RL: BSU (Biological study, unclassified); PNU (Preparation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(thimet oligopeptidase-cleavable prodrug compds.)

RN 274912-87-7 HCAPLUS

CN 5,12-Naphthacenedione, 10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 274912-88-8 HCAPLUS

CN 5,12-Naphthacenedione, 8-acetyl-10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 274912-89-9 HCAPLUS

CN 5,12-Naphthacenedione, 10-[[3-[[N-(4-carboxy-1-oxobutyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT 274912-95-7P 274912-96-8P 274913-03-0P
274913-04-1P 274913-05-2P 274913-07-4P
RL: BSU (Biological study, unclassified); PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(thimet oligopeptidase-cleavable prodrug compds.)

RN 274912-95-7 HCAPLUS

CN L-Leucine, N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 274912-96-8 HCAPLUS

CN L-Leucine, N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 274913-03-0 HCAPLUS

CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-[1,4-dioxo-4-(2-

propenyloxy)butyl]-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 274913-04-1 HCAPLUS

CN L-Leucine, N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 274913-05-2 HCAPLUS

CN L-Leucine, N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 274913-07-4 HCAPLUS

CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L5 ANSWER 9 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:323079 HCAPLUS Full-text

DOCUMENT NUMBER: 137:241802

TITLE: CPI-0004Na, a new extracellularly tumor-activated prodrug of Doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity

AUTHOR(S): Dubois, Vincent; Dasnois, Luc; Lebtahi, Karim; Collot, Francoise; Heylen, Nathalie; Havaux, Nathalie; Fernandez, Anne-Marie; Lobl, Thomas J.; Oliyai, Cecilia; Nieder, Matthew; Shochat, Dan; Yarranton, Geoffrey T.; Trouet, Andre

CORPORATE SOURCE: Universite Catholique de Louvain, Laboratory of Cell Biology, Louvain-la-Neuve, B-1348, Belg.

SOURCE: Cancer Research (2002), 62(8), 2327-2331
CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 274912-87-7
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity of CPI-0004Na)

RN 274912-87-7 HCAPLUS

CN 5,12-Naphthacenedione, 10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:10314 HCAPLUS Full-text

DOCUMENT NUMBER: 136:86054

TITLE: Tripeptide prodrug compounds

INVENTOR(S): Bebbington, Christopher R.; Dubois, Vincent; Gangwar, Sanjeev; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Leslie B.; Trouet, Andre; Yarranton, Geoffrey T.

PATENT ASSIGNEE(S): Corixa Corporation, USA

SOURCE: PCT Int. Appl., 102 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000263	A2	20020103	WO 2001-US40925	20010611
WO 2002000263	A3	20020815		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2411545	AA	20020103	CA 2001-2411545	20010611
EP 1294403	A2	20030326	EP 2001-942249	20010611
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004501875	T2	20040122	JP 2002-505044	20010611
US 2003181359	A1	20030925	US 2002-311519	20021213
PRIORITY APPLN. INFO.:			US 2000-212880P P	20000614
			WO 2001-US40925 W	20010611

OTHER SOURCE(S): CASREACT 136:86054; MARPAT 136:86054

IT 274912-87-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(tripeptide prodrug compds.)

RN 274912-87-7 HCAPLUS

CN 5,12-Naphthacenedione, 10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L5 ANSWER 11 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:923644 HCAPLUS Full-text
DOCUMENT NUMBER: 136:58787
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Nieder, Matthew H.; Dubois, Vincent; Gangwar, Sanjeev; Lobl, Thomas J.; Pickford, Leslie B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Corixa Corporation, USA
SOURCE: PCT Int. Appl., 159 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001095945	A2	20011220	WO 2001-US18903	20010611
WO 2001095945	A3	20020815		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2411660 AA 20011220 CA 2001-2411660 20010611
EP 1294405 A2 20030326 EP 2001-950291 20010611
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004510703 T2 20040408 JP 2002-510122 20010611
PRIORITY APPLN. INFO.: US 2000-211887P P 20000614
US 2001-290448P P 20010511
WO 2001-US18903 W 20010611

OTHER SOURCE(S): MARPAT 136:58787
IT 274912-87-7P 274912-88-8P 274912-89-9P
RL: PAC (Pharmacological activity); PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(enzyme-cleavable prodrug compds.)
RN 274912-87-7 HCAPLUS
CN 5,12-Naphthacenedione, 10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 274912-88-8 HCAPLUS
CN 5,12-Naphthacenedione, 8-acetyl-10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 274912-89-9 HCAPLUS
CN 5,12-Naphthacenedione, 10-[[3-[[N-(4-carboxy-1-oxobutyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L5 ANSWER 12 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:653068 HCAPLUS Full-text
DOCUMENT NUMBER: 135:362468
TITLE: N-succinyl-(β-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin: an extracellularly tumor-activated prodrug devoid of intravenous acute toxicity
AUTHOR(S): Fernandez, Anne-Marie; Van derpoorten, Kim; Dasnois, Luc; Lebtahi, Karim; Dubois, Vincent; Lobl, Thomas J.; Gangwar, Sanjeev; Oliyai, Cecilia; Lewis, Evan R.; Shochat, Dan; Trouet, Andre
CORPORATE SOURCE: Laboratory of Cell Biology, Universite Catholique de Louvain, Louvain-la-Neuve, B-1348, Belg.
SOURCE: Journal of Medicinal Chemistry (2001), 44(22), 3750-3753
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 372491-73-1P
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(N-succinyl-(β-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin: an extracellularly tumor-activated prodrug devoid of i.v. acute toxicity)
RN 372491-73-1 HCAPLUS
CN 5,12-Naphthacenedione, 10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, monosodium salt, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:401690 HCAPLUS Full-text
DOCUMENT NUMBER: 133:48878
TITLE: Oligopeptide prodrug compounds and process for preparation thereof
INVENTOR(S): Lobl, Thomas J.; Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev; Lewis, Evan; Nieder, Matthew H.; Trouet, Andre; Viski, Peter; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2354766	AA	20000615	CA 1999-2354766	19991210
EP 1144011	A2	20011017	EP 1999-967462	19991210
EP 1144011	A3	20020206		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2003518000	T2	20030603	JP 2000-586378	19991210
AU 773420	B2	20040527	AU 2000-23733	19991210
NZ 512171	A	20040730	NZ 1999-512171	19991210
US 2002142955	A1	20021003	US 2001-879442	20010611
PRIORITY APPLN. INFO.:			US 1998-111793P P	19981211
			US 1999-119312P P	19990208
			WO 1999-US30393 W	19991210
			US 2000-211887P P	20000614
			US 2001-290448P P	20010511

OTHER SOURCE(S): MARPAT 133:48878
IT 274912-87-7 274912-88-8 274912-89-9
274912-95-7 274912-96-8 274913-03-0
274913-04-1 274913-05-2 274913-07-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oligopeptide prodrug compds. and process for preparation thereof)

RN 274912-87-7 HCAPLUS
CN 5,12-Naphthacenedione, 10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B



RN 274912-88-8 HCAPLUS
CN 5,12-Naphthacenedione, 8-acetyl-10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B



RN 274912-89-9 HCAPLUS
CN 5,12-Naphthacenedione, 10-[[3-[[N-(4-carboxy-1-oxobutyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B



RN 274912-95-7 HCAPLUS
CN L-Leucine, N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 274912-96-8 HCAPLUS
CN L-Leucine, N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 274913-03-0 HCAPLUS
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-[1,4-dioxo-4-(2-propenyloxy)butyl]-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 274913-04-1 HCAPLUS
CN L-Leucine, N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 274913-05-2 HCAPLUS
CN L-Leucine, N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 274913-07-4 HCAPLUS
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



```
=> DIS HIST

     (FILE 'HOME' ENTERED AT 07:28:10 ON 24 JUN 2005)

     FILE 'REGISTRY' ENTERED AT 07:28:19 ON 24 JUN 2005
L1             STRUCTURE UPLOADED
L2            21 S L1 FUL
                E DOXORUBICIN
L3           109 S E3
L4             0 L3 AND L2

     FILE 'HCAPLUS' ENTERED AT 07:29:39 ON 24 JUN 2005
L5            13 S L2

     FILE 'REGISTRY' ENTERED AT 07:30:13 ON 24 JUN 2005

     FILE 'HCAPLUS' ENTERED AT 07:30:18 ON 24 JUN 2005

=>

---Logging off of STN---


=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                              ENTRY    SESSION
FULL ESTIMATED COST                           48.97     232.72

STN INTERNATIONAL LOGOFF AT 07:31:12 ON 24 JUN 2005
```